Announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer’s disease. ProMIS Neurosciences Inc shares T.PMN are trading unchanged at $6.75.
Stocks in play: ProMIS Neurosciences Inc
Baystreet.ca - Baystreet - Contributor Content
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
/Cisco%20Systems%2C%20Inc_%20magnified%20logo-by%20Pavel%20Kapysh%20via%20Shutterstock.jpg)
/NVIDIA%20Corp%20logo%20on%20phone%20and%20AI%20chip-by%20Below%20the%20Sky%20via%20Shutterstock.jpg)